Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, has named Kim McLean Boericke as its Chief Executive Officer (CEO). Boericke, an experienced executive with decades of leadership and operational experience in the clinical research industry, succeeds Patrick Flanagan, who will transition to Veristat’s Board of Directors. “I’m delighted to pass the baton to Kim at this exciting time for the company. She is a scientifically astute leader...